Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research note released on Monday,Benzinga reports. The firm currently has a $14.00 price objective on the stock.

Several other research analysts have also recently weighed in on the stock. D. Boral Capital restated a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, February 18th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday, February 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Trading Down 0.7%

COYA opened at $4.50 on Monday. The stock has a market capitalization of $94.14 million, a PE ratio of -4.05 and a beta of 0.23. Coya Therapeutics has a 1-year low of $3.94 and a 1-year high of $7.75. The firm has a 50-day moving average price of $4.75 and a two-hundred day moving average price of $5.58.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The company had revenue of $3.96 million for the quarter, compared to analyst estimates of $1.93 million. On average, research analysts predict that Coya Therapeutics will post -1.15 EPS for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Several large investors have recently bought and sold shares of the business. Alyeska Investment Group L.P. bought a new position in Coya Therapeutics in the fourth quarter valued at approximately $4,640,000. AWM Investment Company Inc. bought a new stake in shares of Coya Therapeutics during the 4th quarter valued at $4,205,000. Private Management Group Inc. acquired a new position in shares of Coya Therapeutics in the 4th quarter valued at $1,626,000. Marshall Wace LLP lifted its stake in shares of Coya Therapeutics by 438.8% in the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock valued at $1,307,000 after purchasing an additional 183,533 shares during the period. Finally, Dauntless Investment Group LLC boosted its position in shares of Coya Therapeutics by 199.5% in the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock worth $872,000 after purchasing an additional 101,932 shares during the last quarter. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.